GlassScriptPhysician profile
Abrar M Arshad
NPI 1336211457
$675.82
in general payments reported to CMS, 2019-2025
12 companies · $89.55 in 2025
The $89.55 reported for 2025 was less than what a typical Neurodevelopmental Disabilities (Pediatrics) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $93.94 · 2021: $209 · 2022: $67.98 · 2023: $47.92 · 2024: $19.84 · 2025: $89.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $163.75 | 2019-2021 | |
| Tris Pharma INC | $146.04 | 2019-2022 | |
| Neurelis, INC. | $66.21 | 2020-2021 | |
| Abbott Laboratories | $64.23 | 2025 | Infinity |
| Jazz Pharmaceuticals INC. | $47.92 | 2023 | |
| Sunovion Pharmaceuticals INC. | $41.83 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.63 | 2021 | |
| Astellas Pharma US INC | $30.59 | 2021 | |
| Aucta Pharmaceuticals, INC. | $25.32 | 2025 | Motpoly Xr |
| Acadia Pharmaceuticals INC | $19.84 | 2024 | Daybue |
| Sanofi Pasteur INC. | $17.06 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abrar Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.